NFKB1 and hepatocellular carcinoma: The hepatoma cells (Huh 7 and SNU‐423) treated with NF‐κB inhibitor inhibited the enhancements of TG, glucose, kynurenine, and PD‐L1 induced by the GFP‐core protein as well as MAPK inhibitor (U0126) treatment, an inhibitor of ISX phosphorylation[15] (Figure 5c–f).